Vivian Cabrera Melendez, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 100 Boqueron Bay Villas, Apt 605, Boqueron, PR 00622 Phone: 787-951-3245 Fax: 787-851-2625 |
News Archive
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.
Inc. magazine has ranked Extend Health, Inc. No. 94 on its 29th annual Inc. 500, which was released today. This is the first time the company applied for inclusion on this exclusive list of the nation's fastest-growing private companies. The ranking is based on a 2,579% increase in sales over the past three years, leading to revenue of $36.6 million in 2009. Based on its 2009 revenue, Extend Health would rank No. 14 among the top 100 companies on the 2010 Inc. 500 list.
Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2020 - forecasts the breast cancer treatment market to increase in value from $9.2 billion in 2013 to more than $13.1 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.1%.
A study published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called 'regulatory T cells' for therapeutic use.
› Verified 8 days ago